title: Clinical characteristics of Japanese lung cancer patients with human immunodeficiency virus infection.
abstract: BACKGROUND
  Lung cancer has emerged as a crucial problem among human immunodeficiency virus (HIV)-infected patients, contributing to significant mortality in Western countries. Japan has an increasing number of newly infected HIV patients, but clinical characteristics of lung cancer have not been well investigated in Asian populations with HIV.
  
  
  METHODS
  We retrospectively analyzed patients diagnosed with HIV and lung cancer simultaneously in our institution between 1985 and 2010. Data regarding HIV status, characteristics, treatment, and prognosis of lung cancer were evaluated.
  
  
  RESULTS
  We identified 13 consecutive patients (all men; mean age, 59.0 ± 10.2 years) since 1985, 7 of whom had been diagnosed since 2008. Mean CD4 cell count was 332 ± 159 cells/μL, and HIV viral loads were undetectable in 8 patients (61.5%) at the time of lung cancer diagnosis. The mean latency from HIV diagnosis to detection of lung cancer was 4.0 years. Histological examination demonstrated adenocarcinoma in 9 patients (69.2%), followed by squamous cell carcinoma (23.1%), and small cell carcinoma (7.7%). Among the 7 patients available for examination, 2 patients (28.6%) harbored EGFR mutation. Six patients had stage IA-IIIA, and 7 patients had stage IIIB/IV. Among 6 patients treated with chemotherapy for unresectable stages, 5 (83.3%) achieved a partial response. Median overall survival was 17 months for all stages and 14 months for advanced stages. Toxicities for treatment modalities were largely acceptable.
  
  
  CONCLUSIONS
  Clinical characteristics of Japanese HIV-infected patients with lung cancer resemble those of Western populations. The prognosis for patients in the metastatic stage was better than previously reported.
authors.affiliation: Department of Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo, Tokyo 113-8677, Japan. y-okuma@cick.jp
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Okuma
authors.forename: Naoki
authors.initials: N
authors.lastname: Yanagisawa
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Takagi
authors.forename: Yukio
authors.initials: Y
authors.lastname: Hosomi
authors.forename: Akihiko
authors.initials: A
authors.lastname: Suganuma
authors.forename: Akifumi
authors.initials: A
authors.lastname: Imamura
authors.forename: Mari
authors.initials: M
authors.lastname: Iguchi
authors.forename: Tatsuru
authors.initials: T
authors.lastname: Okamura
authors.forename: Atsushi
authors.initials: A
authors.lastname: Ajisawa
authors.forename: Masahiko
authors.initials: M
authors.lastname: Shibuya
mesh_terms: D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D018288:Carcinoma, Small Cell / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D006801:Humans; D008168:Lung / Q000473:pathology; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies